EFFECTS OF METFORMIN AND GLIBENCLAIMIDE COMBINATION IN IRAQI OBESE PATIENTS WITH METABOLIC SYNDROME

Objective: The prevalence of diabetes mellitus and obesity was increased world-wide as well as in Iraq. Inflammation plays important role in pathogenesis of obesity and type 2 DM. The aim of this study was to investigate the serum levels of the inflammatory markers, insulin resistance, and BMI and lipid profile in obese type 2 diabetic Iraqi patients treated with metformin and glibenclamide. Methods: This cross sectional study was conducted at Baquba Teaching Hospital, Diyala, Iraq; from January - April 2014. Fasting blood of glucose and insuline levels, lipid profile (S. cholesterol, S. triglyceride, and S. HDL), S. Interleukin 6 (IL-6) and C-reactive protein were determined in 30 subjects; 15 healthy control and 15 diabetic obese patients. Results: There was statistically significant difference in BMI, fasting blood sugar, insulin resistance and lipid profile between obese diabetic and control group; inflammatory markers were also significantly elevated in diabetic obese patients compared to healthy control. Conclusion: There is augmented inflammatory response in Iraqi diabetic obese patients which plays role in higher insu­lin resistance in these patients. Levels of inflammatory markers are increased and related to BMI and dyslipidemia in these patients

Effects of sildenafil on lipid profile and glycemic control in patients with type 2 diabetes mellitus and metabolic syndrome

Background: Insulin resistance impairs nitric oxide (NO) bioavailability; obesity promotes a state of metabolic syndrome and damages the vascular endothelium by altering lipid profile. Phosphodiesterase-5 (PDE-5) inhibitors restore NO signaling may improve metabolic parameters through a number of mechanisms. We hypothesized that daily administration of the PDE-5 inhibitor; sildenafil will improve fasting plasma glucose (FPG), triglyceride (TG) levels and body weight, in obese diabetic patients.Methods: Totally, 25 obese diabetic male patients with metabolic syndrome treated with sildenafil 25 mg daily for 3 months. Body weight, FPG levels, and lipid profile were determined monthly.Results: Treatment with sildenafil caused a reduction in fasting glucose levels, fasting TGs, cholesterol, low-density lipoprotein (LDL), very-LDL and increased high-density lipoprotein; body weight was significantly reduced.Conclusion: We have provided the first evidence that sildenafil therapy improve glycemic control, lipid profile and body mass index in diabetic patients with metabolic syndrome